The earnings call highlighted strong growth in the Commercial Pharma segment and successful product launches, particularly in emerging markets. However, the loss of a key contract, adverse currency impacts, increased tax burdens, and challenges in the Manufacturing segment notably affected the overall financial performance.

Company Guidance

During the call, Aspen's executives provided comprehensive guidance and insights into the company's financial performance and strategic direction. They highlighted a strong momentum in Commercial Pharma, contributing to 70-80% of turnover, with double-digit revenue and EBITDA growth at constant exchange rates across all segments, including Prescription Medicines, OTC Medicines, and Injectables. However, they faced challenges such as the unanticipated loss of a material contract, impacting EBITDA by ZAR 2 billion, and retrospective global tax regimes affecting tax rates and impairments. The rand's strength also diluted growth. Looking ahead, Aspen plans to sustain growth in Commercial Pharma, restructure its Finished Dosage Form facility, and tap into new opportunities like GLP-1s. They aim for mid-single-digit growth in Commercial Pharma and a return to positive EBITDA for their Manufacturing segment by FY27, with an emphasis on free cash flow generation. The company is also focusing on reducing net debt and capital expenditures while capitalizing on strategic partnerships and emerging market strengths.

Strong Commercial Pharma Growth

The Commercial Pharma segment, which contributes 70-80% of turnover, showed strong momentum with double-digit constant exchange rate revenue and EBITDA growth.

Successful Launch of Mounjaro

The launch of Mounjaro in South Africa was the most successful in the private market's history, quickly reaching significant sales milestones and expanding the market by 130%.

Positive ESG Achievements

Aspen achieved an 8% increase in access to critical medicines, improved gender diversity in leadership to 32%, and a 24% reduction in carbon emissions.

Strong Cash Flow Performance

Aspen achieved an operating cash conversion rate of 147%, significantly higher than the previous years.

Latin America Portfolio Growth

The acquired Pfizer portfolio in Latin America grew by 34% since its acquisition in November 2023.

Aspen Pharmacare (APNHY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

APNHY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 05, 2026	2026 (Q2)	- / -	0.347	―	―	―
Sep 03, 2025	2025 (Q4)	- / -0.42	0.251	-268.53% (-0.67)
Mar 03, 2025	2025 (Q2)	- / 0.35	0.326	6.44% (+0.02)
Oct 02, 2024	2024 (Q4)	0.57 / 0.25	0.393	-36.13% (-0.14)
Mar 04, 2024	2024 (Q2)	- / 0.33	0.369	-11.65% (-0.04)
Aug 30, 2023	2023 (Q4)	0.48 / 0.39	0.45	-12.67% (-0.06)
Mar 01, 2023	2023 (Q2)	- / 0.37	0.528	-30.11% (-0.16)
Aug 31, 2022	2022 (Q4)	0.48 / 0.45	0.326	38.04% (+0.12)	―	―
Mar 09, 2022	2022 (Q2)	- / 0.53	0.403	31.02% (+0.13)	―	―
Sep 01, 2021	2021 (Q4)	0.38 / 0.33	0.288	13.19% (+0.04)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

APNHY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Sep 03, 2025	$5.83	$5.75	-1.37%
Mar 03, 2025	$8.79	$9.82	+11.72%
Oct 02, 2024	$11.23	$11.26	+0.27%
Mar 04, 2024	$10.18	$10.60	+4.13%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aspen Pharmacare (APNHY) report earnings?

Aspen Pharmacare (APNHY) is schdueled to report earning on Mar 05, 2026, TBA (Confirmed).

What is Aspen Pharmacare (APNHY) earnings time?

Aspen Pharmacare (APNHY) earnings time is at Mar 05, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is APNHY EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing